SureTrader Nadex Advertisement Interactive Brokers Advertisement SureTrader
Home > Boards > US Listed > Medical - Drugs >

Kitov Pharmaceuticals Hldgs L Sponsored ADR (KTOV)

Add KTOV Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 5/26/2017 3:37:04 PM - Followers: 116 - Board type: Free - Posts Today: 0



US Office

1615 Suter’s Lane NW, Washington DC 20007, Tel:  +1-202-965-2215

Israel Office

One Azrieli Center, Round Tower, Tel Aviv 6701101


Kitov Pharmaceuticals Holdings Ltd is an Israel-based company that develops non-steroidal anti-inflammatory drugs
that treat pain without raising blood pressure, thus avoiding the increased risk of heart attacks, strokes or death.

Kitov is developing combination drug products that treat the pain of osteoarthritis without causing cardiovascular problems.
These drugs will not only not need to be labeled with health warnings, but will actually be labeled as reducing the risk of
cardiovascular events. Kitov’s drugs have the potential to improve the health of millions of patients worldwide.
It is expected that physicians will prefer to prescribe them rather than prescribe two separate drugs, to improve their patients’ health and to reduce their own legal exposure.

Kitov is currently focusing two late-stage drugs. Both contain NSAIDs that are widely consumed throughout the world for treating osteoarthritis.
Each of Kitov’s drugs adds to the NSAID a second drug product that reduces hypertension.

KIT-301: Naproxen combined with anti-hypertension. Ready for phase III clinical trial. New Drug Application (NDA) scheduled
for 20-24 months from start of development.
KIT-302: Celecoxib combined with anti-hypertension. Ready for phase III clinical trial. New Drug Application (NDA) scheduled for 2015.

Osteoarthritis, affecting approximately half of all adults over the age of 50, is a degenerative disease of joints that can cause pain and limit mobility.
Exercise and weight control are important therapies for controlling symptoms, but for many patients medication is the next step in pain treatment.
Non-steroidal anti-inflammatory drugs (NSAIDs) are the most commonly used medications for treating osteoarthritis pain.
However, these medications raise blood pressure (hypertension) and thereby increase the risk of heart attacks, strokes, and death.
This has led the US FDA to require including a black box warning in the labeling of all NSAIDs, warning of these increased cardiovascular risks.


Dr. John Paul Waymack – M.D., Sc.D.

Chairman of the Board of Directors and Chief Medical Officer

Dr. Waymack was one of the founders of Kitov Pharmaceuticals and has served as the Chairman of our Board of Directors and Chief Medical Officer since July 2013. Dr. Waymack has over 20 years of experience in the biopharma field. Dr. Waymack is a former academic transplant surgeon and a former FDA medical officer, with over fifteen years of experience in drug development as a consultant to major pharmaceutical companies, including Pfizer, Roche, Pharmacia, Warner Lambert and Searle. During his 10 years of academic career, Dr. Waymack published over 100 scientific essays, mainly in the fields of prostaglandins and immunology. In addition, Dr. Waymack volunteered to the U.S. army, where he was commissioned and served as a Major in the Medical Corp. in the position of Chief of Surgical Research in the U.S. Army’s Institute for Surgical Research. Dr. Waymack was also an associate professor of surgery at the University of Texas Medical Branch and at the University of Medicine and Dentistry of New Jersey.



Dec. 17, 2015 :  Kitov Pharmaceuticals Reports Additional Data from its Phase III Trial on the Beneficial Blood Pressure Effects of KIT-302

November 20, 2015 : Kitov Pharmaceuticals Holdings Announces Pricing of U.S. Initial Public Offering and NASDAQ Listing

October 21, 2015 : Kitov Pharma Announces Completion of Patient Recruitment for the Phase III Clinical Trial for KIT-302


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
KTOV News: Annual and Transition Report (foreign Private Issuer) (20-f) 05/01/2017 05:01:56 PM
KTOV News: Report of Foreign Issuer (6-k) 05/01/2017 10:01:37 AM
KTOV News: Report of Foreign Issuer (6-k) 04/26/2017 04:28:03 PM
KTOV News: Report of Foreign Issuer (6-k) 04/03/2017 06:59:52 AM
KTOV News: Report of Foreign Issuer (6-k) 03/27/2017 05:20:25 PM
#5657   My investment style is very different from most tykundegex 05/26/17 03:37:04 PM
#5656   You loaded around $3.5 last year. I understand DavidW2 05/26/17 03:07:54 PM
#5655   The same question could be asked of ANY tykundegex 05/26/17 10:44:44 AM
#5654   But that is the key for whole discussion. DavidW2 05/26/17 10:04:55 AM
#5653   There's a difference .... at 1,80$ trading at EM 05/26/17 03:20:11 AM
#5652   Hey, if your costs is about $1.8 then DavidW2 05/25/17 08:12:21 PM
#5651   Those are question you should have asked yourself EM 05/25/17 06:20:08 PM
#5650   I know everything you talked about. DavidW2 05/25/17 05:38:30 PM
#5649   Lack of DD doesn't allow you to see EM 05/25/17 11:37:16 AM
#5648   The one that successfully applied for and was tykundegex 05/25/17 11:37:04 AM
#5647   Ok shorty! tmeier 05/25/17 11:18:47 AM
#5646   CEO under investigation. That is the management team DavidW2 05/25/17 11:16:42 AM
#5645   "This company never file NDA before, I suspect tykundegex 05/25/17 10:21:31 AM
#5644   I still have some, I had a lot before. DavidW2 05/25/17 10:10:02 AM
#5643   So you are not anymore "very long" EM 05/25/17 10:05:02 AM
#5642   I was very long before. But scandal news DavidW2 05/25/17 09:53:01 AM
#5641   I "suspect" .... I "would" sell .... Where is EM 05/25/17 09:44:50 AM
#5640   LOL. I just want to say, I would DavidW2 05/25/17 09:39:42 AM
#5639   I think only fools short at a bottom tmeier 05/25/17 09:09:19 AM
#5638   I smell their fear .... EM 05/25/17 09:02:26 AM
#5637   Ok tmeier 05/25/17 06:10:09 AM
#5636   Late June? FDA also needs to accept it. DavidW2 05/25/17 02:24:24 AM
#5635   I think they will file it in late June. tmeier 05/24/17 09:51:08 PM
#5634   NDA might delay to Q3. I doubt that DavidW2 05/24/17 09:22:48 AM
#5633   The warrants ran from this level to over tmeier 05/24/17 08:47:40 AM
#5632   They are in the wrong side of the EM 05/24/17 07:00:00 AM
#5631   Yep you might be my bag holder very soon... Masala 05/23/17 09:20:43 PM
#5630   Good to see you still have your short position. tmeier 05/23/17 08:32:53 PM
#5629   I didn't say that...I just said there might Masala 05/23/17 06:51:49 PM
#5628   Some shortys trying hard EM 05/23/17 04:43:07 PM
#5627   ADRs are a "con" instrumented by the company? tykundegex 05/23/17 03:22:56 PM
#5626   KTOV's ADR is another con the pegging Masala 05/23/17 11:38:22 AM
#5625   Hmm no not now, if the stock would Masala 05/15/17 07:50:52 PM
#5624   You still shorting this? tmeier 05/15/17 05:37:58 PM
#5622   And the Mr Roichman Sheer might be a Masala 05/15/17 11:43:27 AM
#5621   Oops!!! The have sold quite a lot Masala 05/15/17 11:21:57 AM
#5620   Nice find! EM 05/15/17 04:22:36 AM
#5619   Looking at the NDA process online, they are Nojunk 05/15/17 12:41:26 AM
#5618   They also work on NDAs. Later oking at Nojunk 05/15/17 12:40:14 AM
#5617   We don't have enough US institutional ownership, agree. EM 05/14/17 06:04:52 AM
#5616   Nice find tmeier 05/13/17 06:17:37 PM
#5614   Here is a full history of Rocihman Sheer's wiltonio 05/13/17 02:08:59 PM
#5613   The NASDAQ page only includes data from 13F wiltonio 05/13/17 02:06:30 PM
#5612   I was wrong by 210,000 shares, but Masala 05/13/17 01:11:39 PM
#5611   Who do I trust NASDAQ or RISENHOOVER Masala 05/13/17 12:26:33 PM
#5610   Only 2% or 21k shares institutional owned midastouch017 05/13/17 11:58:19 AM
#5609   Great information! Was wondering if you or anyone Nojunk 05/12/17 10:28:24 PM
#5608   One of the Lawyers for KTOV: RBNEWS 05/12/17 12:38:08 PM
#5607   Yeah. Not sure if you seen the RBNEWS 05/12/17 12:30:05 PM
#5606   Discovery hasn't begun. Plaintiffs don't know any scottsmith 05/12/17 12:14:37 PM